HOME >> BIOLOGY >> NEWS
Long-Standing Puzzle Of Immune System Is Solved By UCSF Researchers

Researchers at the University of California San Francisco have solved a decades-long scientific puzzle about how the body's immune system works to combat illness.

In a study also having implications for better understanding cancer, the researchers found that the immune system is able to target virtually any unwanted microscopic invader within the body by subverting the function of an enzyme that normally is used to repair mistakes -- called mutations -- in the genetic material, DNA.

Immunology researchers have long suspected that immune cells take advantage of mutations that arise in genes to generate greater diversity in the genes that encode antibodies, proteins that mark disease agents for destruction. This diversity provides the immune system with a better selection from which to choose the best weapons for fighting disease.

Immunologists previously unearthed evidence indicating that immune cells can even activate mechanisms for producing additional mutations, a process dubbed hypermutation. But until now, none of the key molecular players used by immune cells to generate these mutations had been identified.

The study, co-authored by Mattias Wabl, PhD, professor of microbiology and immunology at UCSF and his laboratory team, is reported in the February 20 issue of Science.

"While mutations are, in general, harmful and unwanted, there is an important exception," Wabl explains. "B cells of the immune system depend on mutations in order to be ready to defend the body against newly arising pathogenic microorganisms.

"Without hypermutation at the immunoglobulin genes, which encode antibodies, we would likely have succumbed to an Andromeda strain long ago," Wabl says, referring to a popular science fiction thriller starring a newly arising microscopic scourge that threatens human life on Earth.

The cellular agent identified by the UCSF researchers as the one used by B c
'"/>

Contact: UCSF News Office
415-476-2557
University of California - San Francisco
20-Feb-1998


Page: 1 2 3 4

Related biology news :

1. Comprehensive Nutritional Status In Patients With Long-Standing Crohn Disease Currently In Remission
2. Puzzle solved on how influenza builds its infectious seeds
3. CAK Activation Of Plant Cell Cycle: Scientists Find Another Piece In The Jigsaw Puzzle To Help Explain Why Plants Do Not Develop Cancer Spontaneously
4. New Finding Suggests "HATs" Are Key To Gene Activation Puzzle
5. Immune systems attack dogs kept on genetic leash
6. Immune system drug may increase availability of liver transplants
7. Immune cells may help deliver cancer vaccines for children
8. Immune response depends on key molecule: Research
9. Applied Biosystems and Immune Tolerance Network announce immunology research agreement
10. Immune system component found common to both humans and worms
11. Immune cells SLAP internal signals together

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Long Standing Puzzle Immune System Solved UCSF Researchers

(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: